MedTrace Logo

Use of Nucala in Severe Asthma

NCT05441059 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2100

Last updated 2022-07-01

No results posted yet for this study

Summary

The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) is set up to harmonise severe asthma management across Europe and unravel underlying heterogeneity in a patient-centred way. Using data from national registries included in the SHARP network, this study aims to evaluate real-world use of Nucala, describe characteristics of patients prescribed with Nucala and evaluate the effectiveness of Nucala in clinically relevant endpoints.

Conditions

  • Asthma Severe Persistent Uncontrolled

Interventions

DRUG

Mepolizumab 100 MG

Treatment with mepolizumab for severe asthma

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-05-01
Completion
2022-05-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05441059 on ClinicalTrials.gov